F
F-star Biotech
Developing a pipeline of novel bispecific antibodies with a therapeutic focus in immuno-oncology and oncology
About F-star Biotech
F-star Therapeutics is a biotechnology company focused on developing next-generation immunotherapies to transform the lives of cancer patients. The company operates in the biopharmaceutical market and primarily serves patients with various types of cancer. F-star's core business revolves around its proprietary bispecific antibody technology, which aims to enhance the immune system's ability to detect and destroy cancer cells. The company generates revenue through the development and commercialization of its drug candidates, as well as through partnerships and collaborations with other pharmaceutical companies. F-star's wholly-owned pipeline includes several first and best-in-class drug candidates designed to prevent tumors from evading the body's defense mechanisms. The business model is centered on advancing these drug candidates through clinical trials and eventually bringing them to market, either independently or through strategic partnerships. The company's mission is to keep its approach patient-focused, simple, and driven by science.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2006
- Headquarters
- Babraham, United Kingdom
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 60.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Immune System, Biotech and Pharma, Hard Tech, DT and LS, uk is8 life sciences, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jul 2020
- Capital deployed
- —
- Preferred round
- MERGER
Latest news
Press, funding announcements and product moves mentioning F-star Biotech.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jun 2022 | $161M | $161M | invoX Pharma | ↗ |
| MERGER✓Other financing | Jul 2020 | $0 | — | Spring Bank Pharmaceuticals | — |
Growth signals
Latest recorded traffic for F-star Biotech is 1.8K monthly website visits, down 14.3% over the last three months. F-star Biotech's team declined 90.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 IGEM TherapeuticsImmuno-oncology IgE antibodies for treating solid tumors |
London, United Kingdom | Operational | 1 | $9.7M | $12M |
 Akamis BioLeading company in developing cancer gene therapies |
Abingdon, United Kingdom | Operational | |||
 GammaDelta TherapeuticsAllogeneic gamma-delta T-cell immunotherapies for cancer treatment |
London, United Kingdom | Acquired | |||
 ScancellClinical-stage immunotherapies for difficult-to-treat cancers |
Oxford, United Kingdom | Operational | |||
 ProkariumOral vaccines for infectious diseases |
London, United Kingdom | Operational | |||
 SpyBiotechNovel vaccine platform using protein superglue technology |
Oxford, United Kingdom | Operational | |||
 Amphista TherapeuticsNext-generation therapeutics for targeted protein degradation |
Great Abington, United Kingdom | Operational | |||
 Cytospire TherapeuticsHarnessing the immune system to create next-generation cancer treatments |
London, United Kingdom | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A7 investors entered at this stage
Aescap
Novo Ventures
M Ventures
MP Healthcare Venture Management
TVM Capital Life Science
SR One- TGTVM Capital Healthcare Partners GmbH
Other known investors3 additional known investors
Bristol-Myers Squibb
invoX Pharma
Spring Bank Pharmaceuticals
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about F-star Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See F-star Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.